Figure 3
Figure 3. Frequencies of single KIR-positive and NKG2C+ CD56dim NK cells are not altered during acute IM. (A) Frequencies of CD56dim NKG2A− NK cells expressing the 7 analyzed KIRs from 1 representative CMV-seronegative IM patient at acute phase and at 1 month. The presence of 1 KIR in a combination is represented by a color code below the graph. (B) Frequencies of single KIR-positive CD56dim NK cells in healthy controls (Ctl, n = 11) and IM patients (n = 10) at acute phase (A) and at 1 month (M1). (C) Frequencies of NKG2C+ CD57+ NK cells within the CD56dim NKG2A− population from 1 CMV-seronegative and 1 CMV-seropositive IM patient at acute phase and at 1 month. (D) Frequencies of NKG2C+ NK cells within the CD56dim NKG2A− NK cell population in CMV-seronegative healthy controls (n = 13), CMV-seronegative (n = 10), and CMV-seropositive (n = 5, red) IM patients at acute phase and at 1 month (n = 2 for CMV-seropositive, red lines).

Frequencies of single KIR-positive and NKG2C+ CD56dim NK cells are not altered during acute IM. (A) Frequencies of CD56dim NKG2A NK cells expressing the 7 analyzed KIRs from 1 representative CMV-seronegative IM patient at acute phase and at 1 month. The presence of 1 KIR in a combination is represented by a color code below the graph. (B) Frequencies of single KIR-positive CD56dim NK cells in healthy controls (Ctl, n = 11) and IM patients (n = 10) at acute phase (A) and at 1 month (M1). (C) Frequencies of NKG2C+ CD57+ NK cells within the CD56dim NKG2A population from 1 CMV-seronegative and 1 CMV-seropositive IM patient at acute phase and at 1 month. (D) Frequencies of NKG2C+ NK cells within the CD56dim NKG2A NK cell population in CMV-seronegative healthy controls (n = 13), CMV-seronegative (n = 10), and CMV-seropositive (n = 5, red) IM patients at acute phase and at 1 month (n = 2 for CMV-seropositive, red lines).

Close Modal

or Create an Account

Close Modal
Close Modal